ChinaDrugStatus

Tazemetostat hydrobromide

氢溴酸他泽司他
Brand: Tazverik / 达唯珂·Oncology / Hematology·Last verified 2026-11-20

EZH2 inhibitor listed in the 2025 Commercial List (#16) for EZH2-mutated r/r follicular lymphoma; not carried into the 2026 Commercial List or 2026 NRDL.

China Approval (NMPA)

Approved
Approval Number(s)
国药准字HJ20250031
Initial Approval Date
Mar 18, 2025
Notice Published
Mar 21, 2025
MAH
Epizyme, Inc. (Epizyme / 和黄医药)
Approved Scope
Monotherapy for adult patients with EZH2-mutation-positive relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

National Reimbursement

Not Listed

Not included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).

Commercial Insurance List

2025 Only (Not in 2026)

Previously listed in the 2025 Commercial Insurance Innovative Drug List (#16). Omitted from the 2026 Commercial List edition.

Approved Products, Dosage Forms & Approval Numbers

1 verified NMPA record
Approval No.Dosage Form & StrengthEvent & ScopeApproval / Notice DateMAH & Source
国药准字HJ20250031
Tablet (片剂)
200mg
Initial Approval

Monotherapy for adult patients with EZH2-mutation-positive relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

单药用于既往接受过至少两种系统性治疗后的EZH2突变阳性复发或难治性滤泡性淋巴瘤(FL)成人患者。

Approved: 2025-03-18
Published: 2025-03-21
Epizyme, Inc.

Change Timeline

  1. (2026-01-01)Commercial List· Catalog published: Dec 7, 2025

    2025 Commercial List · Removed in 2026 Edition (#16)

    Monotherapy for adult EZH2-mutation-positive r/r follicular lymphoma after ≥2 prior systemic therapies (listed in 2025 Commercial List #16; omitted from 2026 edition).

    Chinese original: 单药用于既往接受过至少两种系统性治疗后的EZH2突变阳性复发或难治性滤泡性淋巴瘤(FL)成人患者。

    NHSA · PDF p.4Verified 2026-11-20
  2. (2025-03-18)NMPA Approval· Notice published: Mar 21, 2025

    NMPA Initial Marketing Approval (国药准字HJ20250031 · 200mg)

    Monotherapy for adult patients with EZH2-mutation-positive relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

    Chinese original: 单药用于既往接受过至少两种系统性治疗后的EZH2突变阳性复发或难治性滤泡性淋巴瘤(FL)成人患者。

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

氢溴酸他泽司他片dosage name(NHSA)
Tazverikbrand en(WHO)
达唯珂brand zh(NHSA)

Primary Sources for This Record